Monitoring antibody titers to recombinant core-NS3 fusion polypeptide is useful for evaluating hepatitis C virus infection and responses to interferon-alpha therapy

Young Min Park, Byung Hun Byun, Jong Young Choi, Si Hyun Bae, Boo Sung Kim, Hong Soeb So, Wang-Shick Ryu

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

To evaluate the clinical feasibility of the antibody titer against a chimeric polypeptide (named Core 518), in which a domain of Core and NS3 of hepatitis C virus (HCV) was fused, ELISA was performed in a total of 76 serum samples. Each serum was serially diluted using two-fold dilution method with distilled water into 10 concentrations. They were all positive for second generation anti-HCV assay (HCV EIA II; Abbott Laboratories). Genotyping RT-PCR, quantitative competitive RT-PCR, and RIBA (Lucky Confirm; LG Biotech) were also assayed. Anti-Core 518 antibody was detected in × 12800 or higher dilutions of sera from 35 of 43 chronic hepatitis C (81.4%) and nine of 16 hepatocellular carcinoma sera (56.3%), one of four cirrhosis (25%), 0 of four acute hepatitis C, and one of nine healthy isolated anti-HCV-positive subjects (p=0.0000). The anti-Core 518 antibody titers were well correlated with the presence of HCV RNA in serum (p=0.002). The anti-Core 518 antibody titers decreased significantly in nine of ten responders to IFN-α treatment. Monitoring anti-Core 518 titers may be helpful not only for differentiating the status of HCV infection among patients with various type C viral liver diseases, but also for predicting responses to IFN-α treatment.

Original languageEnglish
Pages (from-to)165-170
Number of pages6
JournalJournal of Korean medical science
Volume14
Issue number2
DOIs
Publication statusPublished - 1999 Jan 1

Fingerprint

Virus Diseases
Interferon-alpha
Hepacivirus
Peptides
Antibodies
Serum
Therapeutics
Polymerase Chain Reaction
Chronic Hepatitis C
Hepatitis C
Liver Diseases
Hepatocellular Carcinoma
Fibrosis
Enzyme-Linked Immunosorbent Assay
RNA
Water

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Park, Young Min ; Byun, Byung Hun ; Choi, Jong Young ; Bae, Si Hyun ; Kim, Boo Sung ; So, Hong Soeb ; Ryu, Wang-Shick. / Monitoring antibody titers to recombinant core-NS3 fusion polypeptide is useful for evaluating hepatitis C virus infection and responses to interferon-alpha therapy. In: Journal of Korean medical science. 1999 ; Vol. 14, No. 2. pp. 165-170.
@article{a19552996ac94622b7922d8351daa0fe,
title = "Monitoring antibody titers to recombinant core-NS3 fusion polypeptide is useful for evaluating hepatitis C virus infection and responses to interferon-alpha therapy",
abstract = "To evaluate the clinical feasibility of the antibody titer against a chimeric polypeptide (named Core 518), in which a domain of Core and NS3 of hepatitis C virus (HCV) was fused, ELISA was performed in a total of 76 serum samples. Each serum was serially diluted using two-fold dilution method with distilled water into 10 concentrations. They were all positive for second generation anti-HCV assay (HCV EIA II; Abbott Laboratories). Genotyping RT-PCR, quantitative competitive RT-PCR, and RIBA (Lucky Confirm; LG Biotech) were also assayed. Anti-Core 518 antibody was detected in × 12800 or higher dilutions of sera from 35 of 43 chronic hepatitis C (81.4{\%}) and nine of 16 hepatocellular carcinoma sera (56.3{\%}), one of four cirrhosis (25{\%}), 0 of four acute hepatitis C, and one of nine healthy isolated anti-HCV-positive subjects (p=0.0000). The anti-Core 518 antibody titers were well correlated with the presence of HCV RNA in serum (p=0.002). The anti-Core 518 antibody titers decreased significantly in nine of ten responders to IFN-α treatment. Monitoring anti-Core 518 titers may be helpful not only for differentiating the status of HCV infection among patients with various type C viral liver diseases, but also for predicting responses to IFN-α treatment.",
author = "Park, {Young Min} and Byun, {Byung Hun} and Choi, {Jong Young} and Bae, {Si Hyun} and Kim, {Boo Sung} and So, {Hong Soeb} and Wang-Shick Ryu",
year = "1999",
month = "1",
day = "1",
doi = "10.3346/jkms.1999.14.2.165",
language = "English",
volume = "14",
pages = "165--170",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "2",

}

Monitoring antibody titers to recombinant core-NS3 fusion polypeptide is useful for evaluating hepatitis C virus infection and responses to interferon-alpha therapy. / Park, Young Min; Byun, Byung Hun; Choi, Jong Young; Bae, Si Hyun; Kim, Boo Sung; So, Hong Soeb; Ryu, Wang-Shick.

In: Journal of Korean medical science, Vol. 14, No. 2, 01.01.1999, p. 165-170.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Monitoring antibody titers to recombinant core-NS3 fusion polypeptide is useful for evaluating hepatitis C virus infection and responses to interferon-alpha therapy

AU - Park, Young Min

AU - Byun, Byung Hun

AU - Choi, Jong Young

AU - Bae, Si Hyun

AU - Kim, Boo Sung

AU - So, Hong Soeb

AU - Ryu, Wang-Shick

PY - 1999/1/1

Y1 - 1999/1/1

N2 - To evaluate the clinical feasibility of the antibody titer against a chimeric polypeptide (named Core 518), in which a domain of Core and NS3 of hepatitis C virus (HCV) was fused, ELISA was performed in a total of 76 serum samples. Each serum was serially diluted using two-fold dilution method with distilled water into 10 concentrations. They were all positive for second generation anti-HCV assay (HCV EIA II; Abbott Laboratories). Genotyping RT-PCR, quantitative competitive RT-PCR, and RIBA (Lucky Confirm; LG Biotech) were also assayed. Anti-Core 518 antibody was detected in × 12800 or higher dilutions of sera from 35 of 43 chronic hepatitis C (81.4%) and nine of 16 hepatocellular carcinoma sera (56.3%), one of four cirrhosis (25%), 0 of four acute hepatitis C, and one of nine healthy isolated anti-HCV-positive subjects (p=0.0000). The anti-Core 518 antibody titers were well correlated with the presence of HCV RNA in serum (p=0.002). The anti-Core 518 antibody titers decreased significantly in nine of ten responders to IFN-α treatment. Monitoring anti-Core 518 titers may be helpful not only for differentiating the status of HCV infection among patients with various type C viral liver diseases, but also for predicting responses to IFN-α treatment.

AB - To evaluate the clinical feasibility of the antibody titer against a chimeric polypeptide (named Core 518), in which a domain of Core and NS3 of hepatitis C virus (HCV) was fused, ELISA was performed in a total of 76 serum samples. Each serum was serially diluted using two-fold dilution method with distilled water into 10 concentrations. They were all positive for second generation anti-HCV assay (HCV EIA II; Abbott Laboratories). Genotyping RT-PCR, quantitative competitive RT-PCR, and RIBA (Lucky Confirm; LG Biotech) were also assayed. Anti-Core 518 antibody was detected in × 12800 or higher dilutions of sera from 35 of 43 chronic hepatitis C (81.4%) and nine of 16 hepatocellular carcinoma sera (56.3%), one of four cirrhosis (25%), 0 of four acute hepatitis C, and one of nine healthy isolated anti-HCV-positive subjects (p=0.0000). The anti-Core 518 antibody titers were well correlated with the presence of HCV RNA in serum (p=0.002). The anti-Core 518 antibody titers decreased significantly in nine of ten responders to IFN-α treatment. Monitoring anti-Core 518 titers may be helpful not only for differentiating the status of HCV infection among patients with various type C viral liver diseases, but also for predicting responses to IFN-α treatment.

UR - http://www.scopus.com/inward/record.url?scp=0033111916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033111916&partnerID=8YFLogxK

U2 - 10.3346/jkms.1999.14.2.165

DO - 10.3346/jkms.1999.14.2.165

M3 - Review article

VL - 14

SP - 165

EP - 170

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 2

ER -